Skip to main content
Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.

Publisher: Bentham Science Publishers

More about this publication?
Volume 9, Number 2, 2013

Articles

Free Content Editorial
pp. i-i(1)
Author: Hadjipavlou-Litina, D.

Favourites:
ADD

Tacrolimus Toxicity Reverses the Inhibitory Effects of Renin Angiotensin System Blockade on PAI-1 Expression in Cardiac Tissue
pp. 83-88(6)
Authors: Agirbasli, Mehmet; Bas Bozkurtlar, Emine; Papila-Topal, Nurdan; Deniz, Hicran; Ogutmen, Betul; Cakalagaoglu, Fulya

Favourites:
ADD

Targeting Lipoxygenases (LOs): Drug Design And Discovery
pp. 89-105(17)
Authors: Pontiki, Eleni; Hadjipavlou–Litina, Dimitra

Favourites:
ADD

Advances in Design and Development of Inhibitors of Nitric Oxide Synthases
pp. 117-141(25)
Authors: Kumar, Harish; P. Gupta, Satya; A. Siddiqui, Anees; Kumar, Vijay

Favourites:
ADD
Favourites:
ADD

Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
pp. 152-160(9)
Authors: O’Neal, Julie; Chesney, Jason

Favourites:
ADD

The Proteasome as a Therapeutic Target for Lung Fibrosis
pp. 161-167(7)
Authors: H.T. Go, Leonard; K. Gangar, Jinal; Jain, Manu

Favourites:
ADD
Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content